- Sandoz acquired the capabilities and assets of drug delivery device company, Coalesce, to further its existing portfolio of respiratory medicines and improve overall patient access.
- This acquisition will help Sandoz to build on its current portfolio of respiratory medicines and boost patient access to complex treatments.
Sandoz, a Novartis division, recently amass a UK-based medical and drug delivery device company, Coalesce Product Development Limited.
Through the terms of the agreement, Sandoz acquired the capabilities and assets of Coalesce to help build on its existing portfolio of respiratory medicines and further improve patient access to high-quality, complex therapies.
“Respiratory and complex generics are areas of relatively high unmet medical need, due largely to their comparatively high technical complexity,” Richard Saynor, CEO of Sandoz, said in the announcement.
“At Sandoz, we have the experience and expertise to succeed in these fields and this acquisition offers us a significant new growth platform, particularly in the US and Europe, reinforcing our commitment to pioneer access for patients.”
A major non-communicable disease, Asthma impacts both children and adults. In 2019, it is estimated to have affected 262 million people. The same year had recorded around 3.23 million deaths due to chronic obstructive pulmonary disease (COPD). The burden of respiratory diseases on healthcare systems and productivity crossed over $380bn annually across 28 EU member states.
With a current portfolio of six in market-products and almost twice as many more products in the pipeline, Sandoz considers respiratory as an important aspect of its long-term growth strategy and plans to explore more opportunities both in-house and externally.
About Sandoz Pharma
Sandoz is a global leader in generic pharmaceuticals and biosimilars.
As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our global portfolio comprises approximately 1,000 molecules, covering all major therapeutic areas, which accounted for 2019 sales of USD 9.7 billion. Our products reach more than 500 million patients.
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/ (Pharmaceutical Databases)